FDA grants Breakthrough Device Designation to pulmonary hypertension early detection AI
Related Articles
J&J Hired Thousands of Data Scientists. Will The Strategy Pay Off?
WSJ: One project—with the Mayo Clinic and a health-technology company called Anumana based in Cambridge, Mass.—aims to speed up diagnosis of high blood pressure in the lungs, or pulmonary hypertension.…November 30, 2023
Building sEHR-BERT: A Custom Language Model for Structured Electronic Health Records – Adapting transformer architecture for the unique challenges of medical coding and structured health data
Why Standard BERT Isn't Enough for Structured EHRs BERT revolutionized natural language processing, but electronic health records (EHRs) present unique challenges that standard language models weren't designed to handle. While BERT…January 22, 2026
Anumana Welcomes Dr. Simos Kedikoglou as New COO
Investor Hangout: Anumana, a prominent player in AI-driven health technology, has recently appointed Dr. Simos Kedikoglou as its new President and Chief Operating Officer (COO). This exciting change will see…January 10, 2025
FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new…June 21, 2023